2019
Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers.
Verplaetse TL, Roberts W, Moore KE, Peltier MR, Oberleitner LM, McKee SA. Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers. Journal Of Clinical Psychopharmacology 2019, 39: 124-128. PMID: 30707118, PMCID: PMC6391212, DOI: 10.1097/jcp.0000000000001004.Peer-Reviewed Original ResearchConceptsAdult daily smokersDoses of guanfacineAdverse eventsMedication levelsDaily smokersTobacco cravingTreatment-emergent adverse eventsExtended-release formulationSimilar pharmacokinetic profileAttention deficit hyperactivity disorderDry mouthLast doseMigraine prophylaxisBlood pressureHeroin withdrawalStable dosingDose equivalencyHeart rateER formulationSmoking outcomesGuanfacinePharmacokinetic profileDrug AdministrationVital signsHyperactivity disorder
2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differencesA preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers
Roberts W, Verplaetse TL, Moore KE, Oberleitner LM, McKee SA. A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers. Human Psychopharmacology Clinical And Experimental 2018, 33: e2660. PMID: 29878501, PMCID: PMC5995328, DOI: 10.1002/hup.2660.Peer-Reviewed Original ResearchConceptsContinuous performance taskInhibitory controlCognitive functioningPerformance taskTobacco withdrawalEffects of doxazosinSustained attentionCognitive performanceWithdrawal symptomsCognitive AssessmentSmoking outcomesMost measuresSelf-reported withdrawal symptomsReaction timeTaskParticipantsFunctioningPredrug levelsΑ1 antagonistTitration periodGreater improvementDoxazosinSmokingSymptomsPreliminary investigation
2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomen